BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Glofitamab: trial readouts and FDA decisions

2 upcoming industry Phase 2/3 readout(s) in the next 90 days, 0 upcoming FDA event(s), 1 readout(s) in the last 180 days and 0 FDA event(s) in the last 12 months. Sponsors: Hoffmann-La Roche, Ryvu Therapeutics SA. Drug names come from ClinicalTrials.gov intervention names and FDA records, lightly normalised; one drug can appear under several names (code, generic, brand).

Upcoming trial readouts

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-12 est.P2Ryvu Therapeutics SANCT06534437 MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01)Non-Hodgkin Lymphoma, B-cellrecruiting178
2026-12-28 est.P1/P2Hoffmann-La RocheNCT04077723 A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination WitLymphoma, Non-Hodgkinactive not recruiting498

Readouts, last 180 days

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-10-22P1/P2Hoffmann-La RocheNCT03533283 An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's LymphomaNon-Hodgkins Lymphomacompleted211

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.